Cargando…

Pathophysiology of reflux oesophagitis: role of Toll-like receptors 2 and 4 and Farnesoid X receptor

The pathogenesis of gastroesophageal reflux disease (GERD) is not fully understood. It involves the activation of mucosal immune-mediated and inflammatory responses. Toll-like receptors (TLR) 2 and TLR4 are pattern-recognition receptors of the innate immune system; they recognize microbial and endog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nortunen, Minna, Väkiparta, Nina, Porvari, Katja, Saarnio, Juha, Karttunen, Tuomo J, Huhta, Heikki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364528/ https://www.ncbi.nlm.nih.gov/pubmed/33686512 http://dx.doi.org/10.1007/s00428-021-03066-w

Ejemplares similares

Carbonic Anhydrases II, IX, and XII in Reflux Esophagitis
por: Nortunen, Minna, et al.
Publicado: (2021)

The Expression of Toll-like Receptors in Normal Human and Murine Gastrointestinal Organs and the Effect of Microbiome and Cancer
por: Huhta, Heikki, et al.
Publicado: (2016)

Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma
por: Huhta, Heikki, et al.
Publicado: (2016)

Intratumoral lactate metabolism in Barrett's esophagus and adenocarcinoma
por: Huhta, Heikki, et al.
Publicado: (2017)

Tenascin-C and fibronectin in normal esophageal mucosa, Barrett’s esophagus, dysplasia and adenocarcinoma
por: Leppänen, Joni, et al.
Publicado: (2017)

Tumour-stroma ratio and prognosis in gastric adenocarcinoma
por: Kemi, Niko, et al.
Publicado: (2018)

Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study
por: Helminen, Olli, et al.
Publicado: (2022)

Loss of toll-like receptor 5 potentiates spontaneous hepatocarcinogenesis in farnesoid X receptor–deficient mice
por: Golonka, Rachel M., et al.
Publicado: (2023)

Toll-Like Receptor 4 Wild Type Homozygozity of Polymorphisms +896 and +1196 Is Associated with High Gastrin Serum Levels and Peptic Ulcer Risk
por: Pohjanen, Vesa-Matti, et al.
Publicado: (2015)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Toll-like receptor 5 and the emerging role of bacteria in carcinogenesis
por: Kauppila, Joonas H., et al.
Publicado: (2013)

Microbiota-induced obesity requires farnesoid X receptor
por: Parséus, Ava, et al.
Publicado: (2017)

Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma
por: Leppänen, Joni, et al.
Publicado: (2018)

The Pathophysiology of Farnesoid X Receptor (FXR) in the GI Tract: Inflammation, Barrier Function and Innate Immunity
por: Anderson, Kemp M., et al.
Publicado: (2021)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma
por: Leppänen, Joni, et al.
Publicado: (2019)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

Cohort profile: a nationwide population-based retrospective assessment of oesophageal cancer in the Finnish National Esophago-Gastric Cancer Cohort (FINEGO)
por: Söderström, Henna K, et al.
Publicado: (2020)

Evolution of pancreatic surgery over time and effects of centralization—a single-center retrospective cohort study
por: Nortunen, Minna, et al.
Publicado: (2023)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Reflux Oesophagitis
por: Smith, P. M.
Publicado: (1990)

Finnish National Esophago-Gastric Cancer Cohort (FINEGO) for studying outcomes after oesophageal and gastric cancer surgery: a protocol for a retrospective, population-based, nationwide cohort study in Finland
por: Kauppila, Joonas H, et al.
Publicado: (2019)

Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019)

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases
por: Wu, Jin-nan, et al.
Publicado: (2020)

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
por: Rausch, Magdalena, et al.
Publicado: (2022)

Monocarboxylate Transporters 1 and 4 and Prognosis in Small Bowel Neuroendocrine Tumors
por: Hiltunen, Niko, et al.
Publicado: (2022)

Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets
por: Unsworth, Amanda J., et al.
Publicado: (2017)

Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration
por: Li, Guodong, et al.
Publicado: (2015)

Bacterial metabolites directly modulate farnesoid X receptor activity
por: Zhang, Xianqin, et al.
Publicado: (2015)

Allosteric modulation of the farnesoid X receptor by a small molecule
por: Gabler, Matthias, et al.
Publicado: (2018)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

Irisin Is Controlled by Farnesoid X Receptor and Regulates Cholesterol Homeostasis
por: Li, Hong, et al.
Publicado: (2019)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
por: Mori, Hideki, et al.
Publicado: (2022)

There is no correlation between signs of reflux laryngitis and reflux oesophagitis in patients with gastro-oesophageal reflux disease symptoms
por: Zelenik, K., et al.
Publicado: (2017)

Toll-like receptors in pathophysiology of liver diseases
por: Kiziltas, Safak
Publicado: (2016)

Structural basis of the farnesoid X receptor/retinoid X receptor heterodimer on inverted repeat DNA
por: Jiang, Longying, et al.
Publicado: (2023)

Divergent expression of bacterial wall sensing Toll-like receptors 2 and 4 in colorectal cancer
por: Paarnio, Karoliina, et al.
Publicado: (2017)

Peroxisome proliferator-activated receptors, farnesoid X receptor, and dual modulating drugs in hypertension
por: Imig, John D.
Publicado: (2023)

NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor
por: Schmidt, Jurema, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ggdr3lqbkrv475fdf6cor6p259